Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (6): 960-968    DOI: 10.31083/j.ejgo.2020.06.2224
Special Issue: Topical Collection "Minimally Invasive Surgery in Gynecological Oncology"
Original Research Previous articles | Next articles
Usefulness of laparoscopic restaging surgery for patients diagnosed with apparent early ovarian/fallopian tubal cancer by a prior surgery, a case control observational study in a single institute in Japan
Hiroshi Yoshida1, 2, *(), Megumi Yamamoto2, 3, Hiroyuki Shigeta2, Miwa Yasaka1, Hiroko Machida1, Masae Ikeda1, Masako Shida1, Takeshi Hirasawa1, Mikio Mikami1
1Department of Obstetrics and Gynecology, Tokai University School of Medicine, Address: 143 Shimokasuya, Isehara, 259-1193, Kanagawa, Japan
2Department of Obstetrics and Gynecology, Yokohama Municipal Citizen's Hospital, Address: 1-1 Mitsuzawa-nishi-cho, Kanagawa-ku, Yokohama, 221-0855, Kanagawa, Japan
3Department of Obstetrics and Gynecology, Fukui Prefectural Hospital, Address: 2-8-1 Yotsui, 910-8526, Fukui, Japan
Download:  PDF(387KB)  ( 121 ) Full text   ( 3 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
This study aimed to demonstrate the feasibility, safety, and short-term oncological outcomes of laparoscopic restaging surgery for patients diagnosed with apparent early ovarian/fallopian tubal cancer by a prior surgery in Japan. A total of 22 patients with apparent early stage ovarian/fallopian tubal cancer underwent laparoscopic restaging surgery. Surgical results and oncological outcomes were retrospectively analyzed. The diagnosis of apparent early stage ovarian/fallopian tubal cancer was determined by prior laparoscopic or laparotomic surgery in 15 cases and 7 cases, respectively. The apparent stages IA, IC, and II were observed in 10, 10, and 2 cases, respectively. The average operation time and estimated blood loss was 266.7 ± 85.7 minutes and 252 ± 388.5 mL, respectively. The average total number of harvested lymph nodes was 88.2 ± 24.4. Up-staging was found in 3 cases (13.6%), 1 case of IIIA1(ii) and 2 cases of IIIB. Lymph node metastasis was detected in 2 cases (9.0%). Intra- and postoperative complications (Clavien-Dindo classification ≥ III) occurred in 4 cases (18.1%). Three patients with recurrence were found during the median observation period of 17 months. All of these patients were diagnosed as stage III during restaging surgery. No recurrence was found in cases of stage I or II. Our study demonstrates that laparoscopic restaging surgery for early stage ovarian/fallopian tubal cancer is feasible and safe, and oncological outcomes are comparable to conventional staging surgery. Further large-scale randomized control studies are necessary to confirm the non-inferiority of laparoscopic restaging surgery compared with open surgery.
Key words:  Ovarian cancer      Laparoscopic surgery      Staging surgery      Laparoscopic lymphadenectomy     
Submitted:  20 August 2020      Accepted:  25 September 2020      Published:  15 December 2020     
*Corresponding Author(s):  HİROSHİ YOSHİDA     E-mail:  h-yoshida@tsc.u-tokai.ac.jp

Cite this article: 

Hiroshi Yoshida, Megumi Yamamoto, Hiroyuki Shigeta, Miwa Yasaka, Hiroko Machida, Masae Ikeda, Masako Shida, Takeshi Hirasawa, Mikio Mikami. Usefulness of laparoscopic restaging surgery for patients diagnosed with apparent early ovarian/fallopian tubal cancer by a prior surgery, a case control observational study in a single institute in Japan. European Journal of Gynaecological Oncology, 2020, 41(6): 960-968.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.06.2224     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I6/960

[1] Francesco Plotti, Bartolone Martina, Terranova Corrado, Luvero Daniela, Scaletta Giuseppe, Gatti Alessandra, Benedetti Panici Pierluigi, Angioli Roberto. Role of human epididymis protein 4 (HE4) as predictor of response to platinum based chemotherapy: a systematic review of literature[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 889-896.
[2] Irina Esteves-Krasteva, José Ángel Minguez, José María Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Gabriel Zozaya-Larequi, Juan Luis Alcázar, Matías Jurado. Complete cytoreductive surgery, the key factor for survival in advanced ovarian cancer. Experience of an intermediate volume hospital[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 906-912.
[3] Sefa Kurt, Selim Kandemir, Onur Yavuz, Meral Koyuncuoglu, Emine Cagnur Ulukus, Murat Celiloglu. Persistent tubal epithelium in ovaries after salpingectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 919-923.
[4] Haci Ozturk Sahin, Zelal Aydin, Ibrahim Ugras Toktas, Cetin Toraman, Ilkbal Temel Yuksel, Alper Seyhan, Ozgur Akbayir. Clinical and prognostic value of pre-operative systemic inflammatory markers in clinical course and prognosis of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 924-930.
[5] Fatih Kose, Songül Alemdaroğlu, Hüseyin Mertsoylu, Ali Ayberk Beşen, Ozan Cem Güler, Seda Yüksel Şimşek, Gürcan Erbay, Cem Önal, Hüsnü Çelik. Clinical characteristics of relapsed ovarian cancer patients with striking response to the bevacizumab at first relapse[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 989-995.
[6] R van de Vrie, E van Werkhoven, M J Rutten, J D Asseler, H S van Meurs, D E Werter, M R Buist, A.H. Zwinderman, C A R Lok, P.M.M. Bossuyt, G G Kenter, P Tajik. Validation of a treatment-selection rule for patients with advanced stage ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 1023-1030.
[7] Buse Güler, Merve Çamlıbel, Samiye Mete. What Do Relatives of Turkish Women with Ovarian Cancer Share on Websites? : A Qualitative Research[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 732-738.
[8] Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.
[9] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
[10] Qinglian Ma, Wenjie Yan, Jing Yang, Haiyan Wang, Weixiang Wang, Minghui Dong. Functional interpretation of ovarian cancer in correlation with ISGF3 expression pattern[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 769-773.
[11] Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.
[12] Jae Hong Sang, Soo-Ho Chung. Is it enough in ovarian cancer staging surgery to laparoscopic surgery? Comparison of surgical methods[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 541-544.
[13] Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.
[14] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[15] Xifang Lv, Amanguli, Ping Yang. The role of sodium hydrosulfide in the proliferation and apoptosis of exogenous SB203580 pre-treated human ovarian cancer cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 622-628.
No Suggested Reading articles found!